PHAR Pharming Group N.V.

QT49

NASDAQ·Healthcare·Biotechnology·Netherlands

Latest market price

12.73

+0.50+4.09%

Overview Short InterestFilings

PHARQT49Pharming Group N.V.·NASDAQ

Overview Short InterestFilings

12.73+4.09%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-7.49%$22.97 RARE+1.24%$16.30 NUVB-3.57%$4.59 TRAX-0.07%$45.05 NTLA-6.50%$11.66 ABSI-12.94%$9.69 URGN+5.01%$34.36 MAZE-3.53%$30.37

Snapshot

Index	—	P/E	39.78	EPS (ttm)	0.32	Insider Own	0.01%	Shs Outstand	70.78M	Perf Week	6.97%

Market Cap	901.01M	Forward P/E	43.55	EPS next Y	0.29	Insider Trans	—	Shs Float	67.32M	Perf Month	30.56%

Enterprise Value	825.01M	PEG	2.33	EPS next Q	0.10			Short Float	0.02%	Perf Quarter	24.07%

Income	24.00M	P/S	2.33	EPS this Y	—			Short Ratio	0.58	Perf Half Y	-22.33%

Sales	386.00M	P/B	3.10	EPS next Y	-2.05%	ROA	5.00%	Short Interest	13.43K	Perf YTD	-27.96%

Book/sh	4.11	P/C	4.74	EPS next 5Y	17.04%	ROE	8.96%	52W High	21.34 -40.35%	Perf Year	-3.12%

Cash/sh	2.68	P/FCF	29.06	EPS past 3/5Y	-37.00% -38.91%	ROIC	4.71%	52W Low	9.11 39.74%	Perf 3Y	27.30%

Dividend Est.	—	EV/EBITDA	16.84	Sales past 3/5Y	22.21% 12.14%	Gross Margin	84.34%	Volatility	3.13% 3.23%	Perf 5Y	31.24%

Dividend TTM	—	EV/Sales	2.14	EPS Y/Y TTM	—	Oper. Margin	6.89%	ATR (14)	0.47	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	2.65	Sales Y/Y TTM	-99.58%	Profit Margin	6.30%	RSI (14)	73.69	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	3.23	EPS Q/Q	200.00%	SMA20	21.34%	Beta	-0.06	Target Price	39.00

Payout	0.00%	Debt/Eq	0.39	Sales Q/Q	20.62%	SMA50	18.63%	Rel Volume	0.82	Prev Close	12.23

Employees	407	LT Debt/Eq	0.36	Earnings	Mar 18	SMA200	-7.45%	Avg Volume	24.43K	Price	12.73

IPO Date	Dec 23, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.86% 0.00%	Net Debt/EBITDA	-1.55	Volume	19,943	Change	4.09%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-23-26	Reiterated	Canaccord Genuity	Buy	$37 → $38
May-08-26	Reiterated	Oppenheimer	Outperform	$41 → $40
Apr-10-26	Initiated	Canaccord on growth potential	Buy	$37
Mar-12-26	Reiterated	H.C. Wainwright	Buy	$37
Nov-07-25	Reiterated	Oppenheimer	Outperform	$41 → $42
Dec-09-24	Reiterated	Jefferies		$14

Latest News· Times ET

Oct-29-26

Oct-29-2602:05PM

Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41Benzinga

Oct-27-26

Oct-27-2612:59PM

Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcriptseekingalpha.com

11:07AM

Pharming Group Q3 Earnings Call Highlightsmarketbeat.com

02:00AM

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in Novemberglobenewswire.com

Oct-23-26

Oct-23-2606:40AM

Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On FridayBenzinga

Oct-22-26

Oct-22-2601:00AM

Pharming Group announces third quarter 2026 revenues above market expectationsglobenewswire.com

Oct-14-26

Oct-14-2602:00AM

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026globenewswire.com

Oct-13-26

Oct-13-2610:07PM

Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety SignalsBenzinga

Sep-30-26

Sep-30-2608:16AM

Pharming Group: Viable Contrarian Buy If Ruconest Stabilizesseekingalpha.com

Sep-29-26

Sep-29-2601:00AM

Pharming announces CEO transitionglobenewswire.com

Sep-25-26

Sep-25-2610:30AM

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSglobenewswire.com

Sep-22-26

Sep-22-2608:16AM

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price TargetBenzinga

01:00AM

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026globenewswire.com

Sep-21-26

Sep-21-2607:05AM

MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHARdefenseworld.net

Sep-16-26

Sep-16-2606:44PM

Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?Yahoo

Company

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	386	376	297	245	—	—	—	—	—
Cost of Goods Sold Incl. D&A	61	46	35	25	—	—	—	—	—
Gross Profit	326	331	262	220	—	—	—	—	—
Selling, General and Administrative Excl. Other	183	117	99	88	—	—	—	—	—
Research and Development	120	100	83	69	—	—	—	—	—
Other Operating Expense	-1	93	83	85	—	—	—	—	—
Operating Income	25	21	-4	-22	—	—	—	—	—
Interest Expense	10	11	9	6	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	19	3	4	16	—	—	—	—	—
Net Income Before Taxes	34	13	-8	-12	—	—	—	—	—
Income Taxes	10	10	3	-1	—	—	—	—	—
Consolidated Net Income	24	3	-12	-11	—	—	—	—	—
Net Income From Continuing Operations	24	3	-12	-11	—	—	—	—	—
Net Income	24	3	-12	-11	—	—	—	—	—
EPS (Recurring)	0.35	0.04	-0.18	-0.14	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.35	0.04	-0.18	-0.14	—	—	—	—	—
EPS (Diluted)	0.32	0.04	-0.18	-0.14	—	—	—	—	—
EBITDA	49	35	16	10	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	39.78	441.75	—	—	—	—	—	—	—
Price To Sales Ratio	2.34	3.34	2.34	3.08	—	—	—	—	—
Gross Margin	84.46	88.03	88.22	89.80	—	—	—	—	—
Operating Margin	6.48	5.59	-1.35	-8.98	—	—	—	—	—
Net Margin	6.22	0.80	-4.04	-4.49	—	—	—	—	—
Shares Outstanding	71	71	69	66	—	—	—	—	—
Market Capitalization	904	1,255	695	754	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.